A study to assess the possibility of using blood-derived biomarkers to predict how well patients with major depression will respond to antidepressents

PI

• Tom Fruchtman-Steinbok (PhD) (Geha Mental Health Center)

‍DESCRIPTION

The study involves generating neuronal cells from MDD patients to further understand the biological underpinnings of the disorder and establish NeuroKaire's (formerly Genetika+) MDD disease model.

The study’s primary objective is to investigate the possibility of using NeuoKaire’s  blood test to predict how well patients with major depressive disorder (MDD) will respond to drug therapy. Furthermore, the study aims to identify specific biological markers associated with treatment responsiveness and resistance in MDD patients;  and explore potential methods for characterizing subgroups of patients based on their biological profiles and identify biological markers that can be used to monitor treatment effectiveness and predict relapse risk.